Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||AsiDNA + Rucaparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AsiDNA||AsiDNA is an oligodeoxyribonucleotide drug that acts as a DNA repair pathway antagonist by mimicking double-stranded DNA breaks and subsequently recruiting DNA repair proteins, thereby preventing the repair of other DNA damaged sites, and thus, potentially leading to increased cell death and inhibition of cell proliferation (PMID: 27559053, PMID: 32839491).|
|Rucaparib||Rubraca||AG014699|PF-01367338|CO-388|AG14447||PARP Inhibitor (Pan) 20||Rubraca (rucaparib) binds to and inhibits PARP, which may result in accumulation of DNA damage and chemosensitization of tumor cells (PMID: 17363489). Rubraca (rucaparib) is FDA approved for use as a maintenance therapy in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, for treatment in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer harboring deleterious somatic and/or germline BRCA mutations who received 2 or more chemotherapies, and in patients with metastatic castration-resistant prostate cancer who received anti-androgen therapy and a taxane-based therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||breast cancer||not applicable||AsiDNA + Rucaparib||Preclinical - Cell culture||Actionable||In a preclinical study, AsiDNA and Rubraca (rucaparib) combination treatment resulted in increased cell death and inhibition of proliferation in breast cancer cell lines compared to Rubraca (rucaparib) alone in culture (PMID: 27559053).||27559053|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|